ARQT
Company Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 376.07M | 196.54M | 59.61M | 3.69M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (16.14M) | (140.04M) | (262.14M) | (311.46M) | (206.36M) | (135.68M) | (42.00M) | (19.25M) | (4.98M) |
| EPS | -0.13 | -1.16 | -3.78 | -5.66 | -4.17 | -3.80 | -1.10 | -0.53 | -4.71 |
| Free Cash Flow | (6.31M) | (112.30M) | (247.49M) | (281.00M) | (175.62M) | (113.35M) | (43.13M) | (14.09M) | (3.77M) |
| FCF / Share | -0.05 | -0.93 | -3.57 | -5.11 | -3.55 | -3.18 | -1.13 | -0.39 | -3.57 |
| Operating CF | (5.62M) | (112.16M) | (247.06M) | (257.71M) | (174.63M) | (113.03M) | (42.84M) | (14.09M) | (3.77M) |
| Total Assets | 432.97M | 348.89M | 341.37M | 449.27M | 408.15M | 298.27M | 107.01M | 51.10M | 3.82M |
| Total Debt | 6.27M | 110.58M | 205.92M | 202.54M | 77.56M | 4.96M | 307,000 | 0 | 966,000 |
| Cash & Equiv | 42.91M | 71.33M | 88.40M | 53.64M | 97.99M | 65.08M | 63.34M | 39.39M | 3.42M |
| Book Value | 189.48M | 157.54M | 88.67M | 209.58M | 297.68M | 270.62M | 101.46M | (23.99M) | (4.99M) |
| Return on Equity | -0.09 | -0.89 | -2.96 | -1.49 | -0.69 | -0.50 | -0.41 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 105.40M | 129.50M | 99.22M | 81.50M | 65.85M | 71.36M | 44.76M | 30.86M | 49.57M | 13.53M | 38.11M | 5.19M |
| Net Income | (11.29M) | 17.39M | 7.41M | (15.89M) | (25.06M) | (10.79M) | (41.54M) | (52.33M) | (35.38M) | (66.28M) | (44.77M) | (70.99M) |
| EPS | -0.09 | 0.14 | 0.06 | -0.13 | -0.20 | -0.09 | -0.33 | -0.42 | -0.32 | -0.72 | -0.73 | -1.16 |
| Free Cash Flow | 2.24M | 26.18M | (1.75M) | 246,000 | (30.99M) | (5.75M) | (34.83M) | (45.12M) | (31.60M) | (56.25M) | (44.05M) | (66.76M) |
| FCF / Share | 0.02 | 0.20 | -0.01 | 0.00 | -0.25 | -0.05 | -0.28 | -0.37 | -0.28 | -0.61 | -0.71 | -1.09 |
| Operating CF | 2.24M | 26.18M | (1.75M) | 324,000 | (30.38M) | (748,000) | (34.69M) | (45.12M) | (31.60M) | (56.24M) | (43.98M) | (66.48M) |
| Total Assets | 460.00M | 432.97M | 370.98M | 352.43M | 344.11M | 348.89M | 437.35M | 444.76M | 478.54M | 341.37M | 292.96M | 320.69M |
| Total Debt | 13.20M | 6.27M | 113.77M | 110.16M | 110.80M | 110.58M | 208.18M | 207.56M | 206.74M | 205.92M | 205.07M | 204.22M |
| Cash & Equiv | 34.76M | 42.91M | 47.12M | 73.05M | 53.10M | 71.33M | 134.85M | 84.89M | 190.71M | 88.40M | 107.47M | 105.11M |
| Book Value | 189.65M | 189.48M | 158.07M | 138.97M | 142.66M | 157.54M | 156.64M | 186.43M | 224.94M | 88.67M | 46.72M | 80.51M |
| Return on Equity | -0.06 | 0.09 | 0.05 | -0.11 | -0.18 | -0.07 | -0.27 | -0.28 | -0.16 | -0.75 | -0.96 | -0.88 |
